Chugai Pharmaceutical Reports Q3 2026 GAAP EPS of ¥228.07 and Revenue of ¥1,068B
Chugai Pharmaceutical Co., Ltd. has released its third-quarter financial results for the 2026 fiscal year. The company reported a GAAP Earnings Per Share (EPS) of ¥228.07 alongside total revenue reaching ¥1,068 billion. The report coincides with broader developments in the pharmaceutical sector involving Roche's Enspryng receiving FDA approval for thyroid eye disease. While specific margin details were not provided in the brief release, the figures establish the company's current financial standing for the third quarter.
Tickers: $RHHBY
Topics: earnings report EPS pharmaceuticals revenue
Read the full article at Seeking Alpha
Part of the story Jack Henry & Associates Reports Record First Quarter Fiscal 2027 Results (17 articles)